Completed PHASE3 INTERVENTIONAL NCT00171678

Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis

Sponsor: Novartis

Interventions Diclofenac Topical Sodium Gel 1%

Updated 6 times since 2017 Last updated: Apr 20, 2012 Started: Oct 31, 2004 Primary completion: Aug 31, 2005 Completion: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Osteearthritis and is currently completed. Novartis leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Parsippany, United States